A potential first-in-class drug for NASH, a mutant-selective degrader of PI3Ka, and a bi-steric inhibitor of mTOR are some examples of this month's MOTM. Learn more about the molecules by navigating to the full reviews on the right which cover: why the molecules matter, how they were discovered, the key steps behind optimization, how the drugs work, why the targets were chosen, interesting toxicology and clinical data, and more. Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Get a free trial to check out substructure search and more features.